PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron-Reference-Cited by-同舟云学术

PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron

Published:2022-04 Issue:4 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Acharya Arpan¹,Pathania Anup S.²,Pandey Kabita¹,Thurman Michellie¹,Vann Kendra R.³,Kutateladze Tatiana G.³,Challagundala Kishore B.²⁴,Durden Donald L.⁵⁶,Byrareddy Siddappa N.¹²⁷⁸^ORCID

Affiliation:

1. Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA

2. Department of Biochemistry and Molecular Biology University of Nebraska Medical Centre Omaha Nebraska USA

3. Department of Pharmacology University of Colorado School of Medicine Aurora Colorado USA

4. The Child Health Research Institute University of Nebraska Medical Center Omaha Nebraska USA

5. Division of Pediatric Hematology‐Oncology Department of Pediatrics Moores Cancer Center UC San Diego School of Medicine La Jolla California USA

6. Levine Cancer Institute Charlotte North Carolina USA

7. Department of Genetics Cell Biology, and Anatomy University of Nebraska Medical Centre Omaha Nebraska USA

8. Division of Clinical Microbiology Department of Laboratory Medicine Karolinska Institute Stockholm Sweden

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.806

Reference10 articles.

1. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants

2. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

3. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

4. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

5. BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of novel and highly selective SARS-CoV-2 main protease inhibitors;Antimicrobial Agents and Chemotherapy;2024-09-03

2. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2;Antiviral Research;2024-07

3. FRET-based in vitro assay for rapid detecting of SARS-CoV-2 entry inhibitors;Chinese Chemical Letters;2024-07

4. Natural hyperoside extracted from hawthorn exhibits antiviral activity against porcine epidemic diarrhea virus in vitro and in vivo;Virology;2024-06

5. COVID-19 drug discovery and treatment options;Nature Reviews Microbiology;2024-04-15